Donahue R E, Kessler S W, Bodine D, McDonagh K, Dunbar C, Goodman S, Agricola B, Byrne E, Raffeld M, Moen R
Clinical Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
J Exp Med. 1992 Oct 1;176(4):1125-35. doi: 10.1084/jem.176.4.1125.
Moloney Murine Leukemia Virus (MoMuLV) causes T cell neoplasms in rodents but is not known to be a pathogen in primates. The core protein and enzyme genes of the MoMuLV genome together with an amphotropic envelope gene are utilized to engineer the cell lines that generate retroviral vectors for use in current human gene therapy applications. We developed a producer clone that generates a very high concentration of retroviral vector particles to optimize conditions for gene insertion into pluripotent hematopoietic stem cells. This producer cell line also generates a much lower concentration of replication-competent virus that arose through recombination. Stem cells from rhesus monkeys were purified by immunoselection with an anti-CD34 antibody, incubated in vitro for 80-86 h in the presence of retroviral vector particles with accompanying replication-competent virus and used to reconstitute recipients whose bone marrow had been ablated by total body irradiation. The retroviral vector genome was detected in circulating cells of five of eight transplant recipients of CD34+ cells and in the circulating cells of two recipients of infected, unfractionated bone marrow mononuclear cells. Three recipients of CD34+ cells had a productive infection with replication-competent virus. Six or seven mo after transplantation, each of these animals developed a rapidly progressive T cell neoplasm involving the thymus, lymph nodes, liver, spleen, and bone marrow. Lymphoma cells contained 10-50 copies of the replication-competent virus, but lacked the retroviral vector genome. We conclude that replication-competent viruses arising from producer cells making retroviral vectors can be pathogenic in primates, which underscores the importance of carefully screening retroviral producer clones used in human trials to exclude contamination with replication-competent virus.
莫洛尼鼠白血病病毒(MoMuLV)可在啮齿动物中引发T细胞肿瘤,但在灵长类动物中并非已知病原体。利用MoMuLV基因组的核心蛋白和酶基因以及一个嗜异性包膜基因来构建细胞系,这些细胞系可产生用于当前人类基因治疗应用的逆转录病毒载体。我们开发了一个生产克隆,它能产生非常高浓度的逆转录病毒载体颗粒,以优化将基因插入多能造血干细胞的条件。该生产细胞系还产生了通过重组产生的浓度低得多的具有复制能力的病毒。用抗CD34抗体通过免疫选择法纯化恒河猴的干细胞,在存在逆转录病毒载体颗粒及伴随的具有复制能力的病毒的情况下于体外培养80 - 86小时,然后用于重建骨髓已被全身照射消融的受体。在8名接受CD34 + 细胞移植的受体中的5名的循环细胞以及2名接受感染的未分离骨髓单个核细胞的受体的循环细胞中检测到了逆转录病毒载体基因组。3名接受CD34 + 细胞的受体发生了具有复制能力的病毒的有效感染。移植后6或7个月,这些动物中的每一只都发展出一种迅速进展的T细胞肿瘤,累及胸腺、淋巴结、肝脏、脾脏和骨髓。淋巴瘤细胞含有10 - 50个具有复制能力的病毒拷贝,但缺乏逆转录病毒载体基因组。我们得出结论,产生逆转录病毒载体的生产细胞产生的具有复制能力的病毒在灵长类动物中可能具有致病性,这突出了在人体试验中仔细筛选逆转录病毒生产克隆以排除具有复制能力的病毒污染的重要性。